Pharmaceutical Sector’s Outdated Web Forms Expose Critical Cybersecurity Risks
The pharmaceutical and life sciences industry, despite heavy investment in advanced R&D and manufacturing, remains vulnerable due to reliance on outdated web forms lacking modern security protocols. These legacy systems used for clinical trial recruitment, adverse event reporting, and regulatory submissions create significant risks, including data breaches, regulatory penalties, and operational disruptions that undermine research integrity and intellectual property protection.
Between January and September 2025, an analysis of 172 recorded incidents revealed that 29.1% of attacks on pharmaceutical firms involved ransomware, while 26.7% were data breaches. The average cost of a pharmaceutical data breach reached $5.1 million per incident exceeding the global average of $4.44 million. Regulatory fines have also intensified, with one-third of breached organizations facing penalties, and the share of fines exceeding $100,000 rising 19.5% year-over-year.
Compliance Failures and Security Gaps
Legacy web forms often fail to meet critical regulatory standards, including FDA 21 CFR Part 11, GDPR, and GxP requirements. Key deficiencies include:
- Lack of tamper-proof audit trails, violating ALCOA+ principles for data integrity.
- Unencrypted data transmission, exposing sensitive information to interception.
- Weak authentication, leaving systems vulnerable to SQL injection, cross-site scripting (XSS), and session hijacking.
GDPR violations carry severe penalties, with fines reaching €20 million or 4% of global revenue, while data sovereignty breaches can result in operational bans in entire countries.
High-Profile Breaches Highlight Industry Vulnerabilities
Recent incidents underscore the operational and financial impact of these weaknesses:
- Inotiv (2025): A ransomware attack encrypted systems, disrupted operations, and compromised 170 GB of sensitive data.
- AEP (Germany, 2025): Partial IT encryption threatened medicine deliveries to 6,000 pharmacies.
- Cencora (2024): A breach exposed data from 27 pharmaceutical and biotech firms, leading to a $40 million settlement in 2025.
Third-Party Risks Amplify Exposure
Pharmaceutical companies relying on third-party platforms face additional vulnerabilities. 87% of firms report being affected by breaches in their vendor ecosystems, with third-party breaches now accounting for 30% of incidents double the 2024 rate. Clinical trial data, worth hundreds of millions, is particularly at risk when legacy forms lack data localization controls or GDPR-compliant transfer safeguards.
The Cost of Inaction
Organizations spend 60-80% of IT budgets maintaining legacy systems, diverting resources from modernization. Yet, the financial toll of breaches persists long-term: 58% of breach costs accumulate after the first year, extending regulatory scrutiny and reputational damage.
Regulatory guidance is clear systems without audit trails, encryption, and role-based access controls must be replaced. As cyber threats evolve, pharmaceutical firms can no longer treat web forms as low-priority infrastructure. The urgency to modernize is not just a compliance issue but a critical defense against escalating cyber risks.
Inotiv cybersecurity rating report: https://www.rankiteo.com/company/inotiv
Cencora cybersecurity rating report: https://www.rankiteo.com/company/cencoraglobal
"id": "INOCEN1775802306",
"linkid": "inotiv, cencoraglobal",
"type": "Breach",
"date": "1/2025",
"severity": "100",
"impact": "4",
"explanation": "Attack with significant impact with customers data leaks"{'affected_entities': [{'industry': 'pharmaceutical/life sciences',
'name': 'Inotiv',
'type': 'pharmaceutical'},
{'customers_affected': '6,000 pharmacies',
'industry': 'pharmaceutical/life sciences',
'location': 'Germany',
'name': 'AEP (Germany)',
'type': 'pharmaceutical'},
{'customers_affected': '27 pharmaceutical and biotech '
'firms',
'industry': 'pharmaceutical/life sciences',
'name': 'Cencora',
'type': 'pharmaceutical/biotech'}],
'attack_vector': ['SQL injection',
'cross-site scripting (XSS)',
'session hijacking',
'third-party breaches'],
'data_breach': {'data_encryption': 'partial IT encryption (AEP)',
'data_exfiltration': '170 GB (Inotiv)',
'personally_identifiable_information': 'yes',
'sensitivity_of_data': 'high (worth hundreds of millions)',
'type_of_data_compromised': ['clinical trial data',
'adverse event reports',
'regulatory submission data',
'personally identifiable '
'information']},
'description': 'The pharmaceutical and life sciences industry remains '
'vulnerable due to reliance on outdated web forms lacking '
'modern security protocols. These legacy systems used for '
'clinical trial recruitment, adverse event reporting, and '
'regulatory submissions create significant risks, including '
'data breaches, regulatory penalties, and operational '
'disruptions that undermine research integrity and '
'intellectual property protection.',
'impact': {'brand_reputation_impact': 'Reputational damage, long-term '
'scrutiny',
'data_compromised': ['170 GB of sensitive data (Inotiv)',
'clinical trial data',
'adverse event reports',
'regulatory submission data'],
'downtime': 'Disrupted operations (Inotiv), threatened medicine '
'deliveries to 6,000 pharmacies (AEP)',
'financial_loss': '$5.1 million per incident (average data breach '
'cost)',
'legal_liabilities': ['$40 million settlement (Cencora)',
'regulatory fines exceeding $100,000'],
'operational_impact': ['disrupted research integrity',
'operational disruptions',
'medicine delivery threats'],
'systems_affected': ['legacy web forms',
'IT systems (partial encryption in AEP case)',
'third-party vendor platforms']},
'lessons_learned': 'Legacy web forms lacking audit trails, encryption, and '
'role-based access controls must be modernized to comply '
'with regulatory standards and mitigate cyber risks. '
'Third-party vendor ecosystems pose significant additional '
'risks.',
'post_incident_analysis': {'corrective_actions': ['modernize legacy systems',
'implement audit trails',
'enforce encryption',
'strengthen authentication',
'enhance third-party risk '
'management'],
'root_causes': ['outdated web forms',
'lack of encryption',
'weak authentication',
'third-party vulnerabilities',
'non-compliance with regulatory '
'standards']},
'ransomware': {'data_encryption': 'yes (Inotiv, AEP)',
'data_exfiltration': 'yes (Inotiv)'},
'recommendations': 'Replace outdated web forms with modern, secure '
'alternatives featuring tamper-proof audit trails, '
'encrypted data transmission, and strong authentication. '
'Implement data localization controls and GDPR-compliant '
'transfer safeguards for clinical trial data. Allocate IT '
'budgets to prioritize modernization over legacy system '
'maintenance.',
'references': [{'source': 'Industry analysis (2025)'}],
'regulatory_compliance': {'fines_imposed': ['€20 million or 4% of global '
'revenue (GDPR)',
'$100,000+ (one-third of breached '
'organizations)'],
'legal_actions': ['$40 million settlement '
'(Cencora)'],
'regulations_violated': ['FDA 21 CFR Part 11',
'GDPR',
'GxP requirements',
'ALCOA+ principles']},
'title': 'Pharmaceutical Sector’s Outdated Web Forms Expose Critical '
'Cybersecurity Risks',
'type': ['ransomware', 'data breach'],
'vulnerability_exploited': ['lack of tamper-proof audit trails',
'unencrypted data transmission',
'weak authentication',
'outdated web forms']}